Table 4 Treatment-related adverse events
n (%) | TACE plus apatinib plus camrelizumab (n = 80) | |
|---|---|---|
All grade | Grade ≥ 3 | |
Hand-foot skin reaction | 33 (41.3) | 5 (6.3) |
Hypertension | 35 (43.8) | 6 (7.5) |
Fatigue | 16 (20.0) | 2 (2.5) |
Mouth ulcers | 5 (6.3) | 0 (0) |
Proteinuria | 25 (31.3) | 1 (1.3) |
Rash | 11 (13.8) | 0 (0) |
Hoarseness | 4 (5.0) | 0 (0) |
Gingival hamorrhage | 3 (3.8) | 0 (0) |
Decreased appetite | 14 (17.5) | 0 (0) |
Diarrhoea | 13 (16.3) | 2 (2.5) |
Hypothyroidism | 15 (18.8) | 0 (0) |
Hyperthyroidism | 3 (3.8) | 0 (0) |
RCCEP | 16 (20.0) | 0 (0) |
Myocarditis | 3 (3.8) | 1 (1.3) |
Haemorrhage, upper GI | 3 (3.8) | 0 (0) |